WO2022135514A1 - Dérivés d'uracile multi-substitués et leur utilisation - Google Patents

Dérivés d'uracile multi-substitués et leur utilisation Download PDF

Info

Publication number
WO2022135514A1
WO2022135514A1 PCT/CN2021/140771 CN2021140771W WO2022135514A1 WO 2022135514 A1 WO2022135514 A1 WO 2022135514A1 CN 2021140771 W CN2021140771 W CN 2021140771W WO 2022135514 A1 WO2022135514 A1 WO 2022135514A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
atoms
compound
present
methyl
Prior art date
Application number
PCT/CN2021/140771
Other languages
English (en)
Chinese (zh)
Inventor
张铮
韩伟
马发城
池波
刘楚怡
王慧
詹志柱
贺艳
李明
王晓军
左应林
Original Assignee
广东东阳光药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东东阳光药业有限公司 filed Critical 广东东阳光药业有限公司
Publication of WO2022135514A1 publication Critical patent/WO2022135514A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention belongs to the field of pharmaceutical technology, and specifically relates to novel polysubstituted uracil derivatives and pharmaceutical compositions containing these compounds, and further relates to their use methods and uses.
  • the polysubstituted uracil derivatives or their pharmaceutical compositions of the present invention can be used as chymotrypsin-like inhibitors for preventing, treating or alleviating cardiovascular diseases such as heart failure or myocardial infarction.
  • CVD Cardiovascular diseases
  • CVD refers to ischemic or hemorrhagic diseases of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc., such as hypertension, coronary artery disease, myocardial disease, Vascular disease, congenital heart disease, arrhythmia, pericardial disease, heart attack and stroke, etc.
  • hypertension, high cholesterol, smoking, obesity and diabetes are major risk factors for the development of cardiovascular disease.
  • Health conditions such as lifestyle, age, and family history can also increase the risk of heart disease.
  • Chymase is a chymotrypsin-like serine protease whose macromolecular complex with heparin is stored in secretory vesicles of mast cells. After mast cells are activated, chymase is released into the extracellular matrix in response to inflammatory signals, tissue damage and cellular stress. Growing evidence suggests that mast cell chymase is one of the key factors contributing to tissue remodeling and CVD progression. Activated mast cells play an important role in wound healing and inflammation resolution, such as wound fibrosis, angiogenesis and myocardial remodeling (Miyazaki et al., Pharmacol. Ther, 112 (2006), 668-676; Shiota et al, J. Hypertens, 21 (2003), 1823-1825).
  • chymotrypsin-like enzymes are also suspected to be one of the causes of various nephropathy such as diabetic nephropathy and polycystic kidney disease (Huang et al., J.Am.Soc.Nephrol, 14(7), (2003), 1738-1747 ; McPherson et al., J. Am. Soc. Nephrol, 15(2), (2004), 493-500).
  • Chymotrypsin-like enzymes are mainly involved in the production of angiotensin II in the heart, arterial walls and lungs.
  • An earlier study by Cleveland Clinic investigators was the first to demonstrate the role of chymase as an Ang II (angiotensin II)-forming enzyme (Urata H et al., J. Biol. Chem, 1990, 265(36):22348-57).
  • Ang II angiotensin II
  • Ang II angiotensin II
  • Ang II is an effector molecule that mainly acts on various target receptors on the surface of vascular wall cells, nuclear membranes, renal tubules, glomeruli, and adrenal glands to achieve blood pressure regulation and water and electrolyte balance. control.
  • angiotensin II When angiotensin II binds to angiotensin receptors, it causes corresponding physiological effects, including constricting arterioles and veins throughout the body, increasing blood pressure, and increasing blood return to the heart; stimulating the adrenal gland to synthesize and release aldosterone. Therefore, inhibiting the activation of chymotrypsin can reduce the production of angiotensin, which can control the contraction of blood vessels and the increase of blood pressure to a certain extent.
  • chymotrypsin-like inhibitors are very useful for the treatment of myocardial infarction (Jin et al., Pharmacol. Exp. Ther, 309 (2004), 409-417), experiments have shown that when coronary artery ligation in dogs causes ventricular arrhythmias, Promotes the production of angiotensin II in the heart and enhances chymotrypsin-like activity.
  • Bayer is developing an oral small-molecule chymotrypsin-like inhibitor BAY-1142524 for the treatment of heart failure and diabetic nephropathy.
  • Phase I clinical results show that the compound can improve cardiac function in hamsters after myocardial infarction.
  • the Phase I clinical results also showed good safety, tolerability and pharmacokinetic properties of BAY-1142524 in healthy subjects.
  • Bayer has launched a phase II clinical trial for diabetic nephropathy to further verify the efficacy and safety of the new chymotrypsin-like inhibitor.
  • chymotrypsin-like inhibition constitutes an effective method of treating cardiovascular disorders, inflammation, allergic disorders and various fibrotic disorders.
  • the present invention provides a class of novel multi-substituted uracil derivatives as chymotrypsin-like inhibitors for preventing, treating or alleviating related cardiovascular diseases such as heart failure or myocardial infarction. And experiments show that the multi-substituted uracil derivatives of the present invention have stable properties, good safety, good pharmacodynamics and pharmacokinetic properties, such as good chymotrypsin-like inhibitory activity, good bioavailability and / or good metabolic stability, etc. Therefore, the compounds of the present invention have good clinical application prospects.
  • the present invention also provides methods for preparing such compounds, pharmaceutical compositions containing such compounds, and the use of such compounds and/or pharmaceutical compositions of such compounds in the preparation of medicaments.
  • the present invention relates to a compound, which is a compound represented by formula (I), or a stereoisomer, tautomer, nitrogen oxide, hydrate, or solvate of the compound represented by formula (I). , a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,
  • each of R 1 , R 2 , R 3 and R 4 has the meaning as described in the present invention.
  • R 1 is H, D, (C 1 -C 6 )-alkyl, halo(C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, or - SO 2 R a , wherein said (C 1 -C 6 )-alkyl, halo(C 1 -C 6 )-alkyl and (C 3 -C 7 )-cycloalkyl are independently unsubstituted or substituted with 1, 2, 3 or 4 R b ;
  • R a is (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, heterocyclyl consisting of 3-8 atoms, C 6-10 aryl or consisting of 5-10 atoms the heteroaryl;
  • R2 is wherein each R 5 is independently H, D, halogen, (C 1 -C 6 )-alkyl, halo(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, or halo Substituted (C 1 -C 6 )-alkoxy; m is 0, 1, 2, 3 or 4;
  • R 6 is -NR n , -O-, -S- or -CR c R d -;
  • R 7 is H, D, (C 1 -C 6 )-alkyl, halo(C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl or composed of 3-8 atoms Heterocyclyl;
  • R n is H, D, (C 1 -C 6 )-alkyl, halo(C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl or composed of 3-8 atoms Heterocyclyl;
  • R c and R d are each independently H, D, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, halo(C 1 -C 6 )-alkoxy or halo(C 1 -C 6 )-alkyl;
  • R 4 is H, D, halogen or (C 1 -C 6 )-alkyl.
  • R 2 is R 5 has the meaning described in the present invention.
  • each R 5 is independently H, D, halogen, (C 1 -C 4 )-alkyl, halo(C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkyl, (C 1 -C 4 )- Alkoxy or halo(C 1 -C 4 )-alkoxy.
  • each R is independently H, D, F, Cl, Br, difluoromethyl, trifluoromethyl, methyl, ethyl, n-propyl, isopropyl, difluoromethoxy group, trifluoromethoxy, methoxy or ethoxy.
  • the compound of the present invention is the compound represented by formula (II-A) or formula (II-B) or its stereoisomer, tautomer, nitrogen oxide, hydrate, solvate , a metabolite, a pharmaceutically acceptable salt or its prodrug:
  • R 1 , R 4 , R 5 , R 6 and R 7 each independently have the meanings described in the present invention.
  • R 1 is (C 1 -C 6 )-alkyl, halo(C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, or -SO 2 R a , wherein the (C 1 -C 6 )-alkyl, halo(C 1 -C 6 )-alkyl and (C 3 -C 7 )-cycloalkyl groups are independently unsubstituted or substituted by 1, 2 , 3 or 4 R b substitutions, wherein R a and R b have the meanings described herein.
  • R 1 is (C 1 -C 4 )-alkyl, halo(C 1 -C 4 )-alkyl, (C 3 -C 6 )-cycloalkyl, or -SO 2 R a , wherein the (C 1 -C 4 )-alkyl, halo(C 1 -C 4 )-alkyl and (C 3 -C 6 )-cycloalkyl groups are independently unsubstituted or substituted by 1, 2 , 3 or 4 R b substitutions, wherein R a and R b have the meanings described herein.
  • R1 is methyl, ethyl, n - propyl , isopropyl, -CF3 , -CH2CF3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or -SO 2 R a ; wherein said methyl, ethyl, n-propyl, isopropyl, -CH 2 CF 3 , cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl are independently unsubstituted or by 1 , 2, 3 or 4 R b substitutions, wherein R a and R b have the meanings described herein.
  • R a is (C 1 -C 4 )-alkyl, (C 3 -C 6 )-cycloalkyl, heterocyclyl of 3-6 atoms, C 6-10 aryl, or Heteroaryl groups consisting of 5-6 atoms.
  • R a is methyl, ethyl, n-propyl, isopropyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5-6 atoms of hetero Cyclic, phenyl, pyridyl, pyrimidinyl, thiazolyl, pyrazolyl, pyrrolyl, imidazolyl or thienyl.
  • R 1 in the present invention is (C 3 -C 6 )-cycloalkyl or -SO 2 R a , wherein R a is (C 1 -C 6 )-alkyl or (C 3 -C 6 ) )-cycloalkyl.
  • R 1 in the present invention is -SO 2 R a , wherein R a is (C 1 -C 6 )-alkyl or (C 3 -C 6 )-cycloalkyl.
  • R a is (C 1 -C 6 )-alkyl or (C 3 -C 6 )-cycloalkyl.
  • the (C 3 -C 6 )-cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; in some embodiments, the (C 1 -C 6 ) -Alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl.
  • R 7 is H, D, (C 1 -C 4 )-alkyl, halo(C 1 -C 4 )-alkyl, (C 3 -C 6 )-cycloalkyl, or 3 -Heterocyclyl consisting of 6 atoms;
  • R n is H, D, (C 1 -C 4 )-alkyl, halo(C 1 -C 4 )-alkyl, (C 3 -C 6 )-cycloalkyl or composed of 3-6 atoms Heterocyclyl;
  • R c and R d are each independently H, D, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, halo(C 1 -C 4 )-alkoxy or Halo(C 1 -C 4 )-alkyl.
  • R 7 is H, D, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclo Hexyl;
  • R n is H, D, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
  • R c and R d are each independently H, D, -CHF 2 , -CF 3 , -CH 2 CF 3 , methoxy, ethoxy, trifluoromethoxy, methyl, ethyl, n-propyl or isopropyl.
  • R4 is H, D, F, Cl, Br, methyl, ethyl, n-propyl, or isopropyl.
  • the compound described in the present invention is a compound having one of the following structures or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, Metabolite, pharmaceutically acceptable salt or its prodrug:
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of the present invention; optionally, it further comprises a pharmaceutically acceptable excipient, carrier, adjuvant or any combination thereof.
  • the pharmaceutical composition of the present invention further comprises one or more other active ingredients selected from calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin antagonists, renin inhibitors, alpha-blockers, beta-blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors, diuretics, kinase inhibitors, Matrix metalloproteinase inhibitors, soluble guanylate cyclase stimulators and activators, and phosphodiesterase inhibitors.
  • active ingredients selected from calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin antagonists, renin inhibitors, alpha-blockers, beta-blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors, diuretics, kinase inhibitors, Matrix metalloproteinase inhibitors,
  • the present invention relates to the use of the compound of the present invention or the pharmaceutical composition of the present invention in the preparation of a medicament, wherein the medicament is used for the treatment or prevention of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, Asthma, kidney failure, kidney disease, fibrotic conditions of internal organs, or skin fibrosis.
  • the present invention relates to methods for the preparation, isolation and purification of compounds represented by formula (I), formula (II-A) or formula (II-B).
  • the biological test results show that the compound of the present invention has a good activity of inhibiting chymotrypsin, and can be used as a good chymotrypsin inhibitor, thereby having the potential effect of preventing the occurrence and progression of related diseases.
  • R 1 is (C 3 -C 6 )-cycloalkyl or -SO 2 R a (wherein R a is (C 1 -C 6 )-alkyl or (C 3 -C 6 )-cycloalkyl Alkyl)
  • the compounds of the present invention have better chymotrypsin-like inhibitory activity.
  • the compound of the present invention has Optimal chymotrypsin-like inhibitory activity.
  • any embodiment of any aspect of the invention may be combined with other embodiments so long as they do not appear to be inconsistent.
  • any technical feature may be applicable to that technical feature in other embodiments, as long as they do not contradict.
  • the articles “a”, “an” and “the” are intended to include “at least one” or “one or more” unless stated otherwise or otherwise clearly contradicted by context.
  • these articles refer to articles of one or more than one (ie, at least one) object.
  • a component refers to one or more components, ie, there may be more than one component contemplated for use or use in the implementation of the described embodiments.
  • stereoisomers refers to compounds that have the same chemical structure, but differ in the arrangement of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis/trans isomers), atropisomers, etc. .
  • chiral molecule is a molecule that has the property of being non-superimposable with its mirror image; whereas an “achiral molecule” refers to a molecule that is superimposable with its mirror image.
  • enantiomer refers to two nonsuperimposable, but mirror-image isomers of a compound.
  • racemate or “racemic mixture” refers to an equimolar mixture of two enantiomers lacking optical activity.
  • diastereomer refers to a stereoisomer having two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers have different physical properties such as melting point, boiling point, spectral properties and reactivity. Diastereomeric mixtures can be separated by high resolution analytical procedures such as electrophoresis and chromatography, eg HPLC.
  • optically active compounds Many organic compounds exist in optically active forms, that is, they have the ability to rotate the plane of plane-polarized light.
  • the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about one or more of its chiral centers.
  • the prefixes d and 1 or (+) and (-) are symbols used to designate the rotation of plane polarized light by the compound, where (-) or 1 indicates that the compound is levorotatory.
  • Compounds prefixed with (+) or d are dextrorotatory.
  • a specific stereoisomer is an enantiomer, and a mixture of such isomers is called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur when there is no stereoselectivity or stereospecificity in a chemical reaction or process.
  • any asymmetric atom (eg, carbon, etc.) of the compounds disclosed herein may exist in racemic or enantiomerically enriched forms, such as (R)-, (S)- or (R,S)-configurations exist.
  • each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 70% enantiomeric excess in the (R)- or (S)-configuration 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess.
  • the compounds of the present invention may be present as one of the possible isomers or as mixtures thereof, such as racemates and diastereoisomeric mixtures (depending on the number of asymmetric carbon atoms) ) in the form of.
  • Optically active (R)- or (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be in the E or Z configuration; if the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have the cis or trans configuration.
  • the resulting mixtures of any stereoisomers may be separated into pure or substantially pure geometric isomers, enantiomers, diastereomers on the basis of differences in the physicochemical properties of the components, for example, by chromatography and/or fractional crystallization.
  • any resulting racemate of the final product or intermediate can be resolved into the optical enantiomers by known methods by methods familiar to those skilled in the art, eg, by performing diastereomeric salts thereof obtained. separation. Racemic products can also be separated by chiral chromatography, eg, high performance liquid chromatography (HPLC) using chiral adsorbents.
  • enantiomers can be prepared by asymmetric synthesis, for example, see Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2 nd Ed. Robert E.
  • tautomer or "tautomeric form” refers to structural isomers having different energies that are interconvertible through a low energy barrier. A chemical equilibrium of tautomers can be achieved if tautomerism is possible (eg, in solution).
  • protontautomers also known as prototropic tautomers
  • prototropic tautomers include interconversions by migration of protons, such as keto-enol isomerization and imine-ene Amine isomerization.
  • “Pharmaceutically acceptable” means compounds, materials, compositions, and/or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with patient tissue without undue toxicity, irritation, allergy, or compatibility with reasonable The benefit/risk ratio is symmetric with other problems and complications and is effective for the intended use.
  • substituted means that one or more hydrogen atoms in a given structure or group have been replaced with a specified substituent. Unless otherwise indicated, a substituent may be substituted at each reasonable position in the group that is substitutable. When more than one position in a given formula can be substituted by one or more specific substituents selected from the group, the substituents may be substituted identically or differently at each reasonable position in the formula.
  • subject refers to an animal. Typically the animal is a mammal.
  • a subject also refers to primates (eg, humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, and the like.
  • the subject is a primate. In other embodiments, the subject is a human.
  • patient refers to humans (including adults and children) or other animals. In some embodiments, “patient” refers to a human.
  • C1 - C6 alkyl specifically refers to the independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl groups.
  • D represents a single deuterium atom.
  • cyano refers to the group -CN.
  • amino refers to the groups -NH2 , -OH and -SH, respectively.
  • halogen refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
  • alkyl refers to a saturated straight or branched chain monovalent hydrocarbon group containing 1 to 20 carbon atoms. In some embodiments, alkyl groups contain 1-12 carbon atoms; in other embodiments, alkyl groups contain 1-6 carbon atoms, ie, C1-6 alkyl, C1 - C 6 alkyl or (C 1- C 6 )-alkyl; in still other embodiments, the alkyl group contains 1-4 carbon atoms, i.e.
  • the alkyl group contains 1-3 carbon atoms, ie, C 1-3 alkyl, C 1- C 3 alkyl, or (C 1- C 3 )-Alkyl.
  • the C 1-6 alkyl described in the present invention includes C 1-4 alkyl; in other embodiments, the C 1-6 alkyl described in the present invention includes C 1-3 alkyl.
  • alkyl groups include, but are not limited to, methyl (Me, -CH3 ), ethyl (Et, -CH2CH3), n - propyl (n - Pr, -CH2CH2CH3 ) ), isopropyl (i-Pr, -CH(CH 3 ) 2 ), n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ), isobutyl (i-Bu, -CH 2 CH ) (CH 3 ) 2 ), sec-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), tert-butyl (t-Bu, -C(CH 3 ) 3 ), n-pentyl (-CH 2CH2CH2CH2CH3), 2 -pentyl (-CH( CH3 ) CH2CH2CH3 ) , 3 - pentyl (-CH( CH2CH3 ) 2 ) , 2 -methyl
  • alkoxy means that an alkyl group is attached to the remainder of the molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy groups contain 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-6 carbon atoms; in other embodiments, the alkoxy group contains 1-4 carbon atoms; in still other embodiments, the alkoxy group The group contains 1-3 carbon atoms.
  • alkoxy groups include, but are not limited to, methoxy (MeO, -OCH 3 ), ethoxy (EtO, -OCH 2 CH 3 ), 1-propoxy (n-PrO, n- Propoxy, -OCH 2 CH 2 CH 3 ), 2-propoxy (i-PrO, i-propoxy, -OCH(CH 3 ) 2 ), 1-butoxy (n-BuO, n- Butoxy, -OCH 2 CH 2 CH 2 CH 3 ), 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH 2 CH(CH 3 ) 2 ), 2-butanyl Oxy (s-BuO, s-butoxy, -OCH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC(CH 3 ) 3 ), 1 -pentyloxy (n - pentyloxy, -OCH2CH2CH2CH2CH2
  • haloalkoxy refers to an alkoxy group substituted with one or more halogen atoms, wherein alkoxy has the meaning described herein; such examples include, but are not limited to, difluoromethoxy ( -OCHF 2 ), trifluoromethoxy (-OCF 3 ) and the like.
  • haloalkyl means an alkyl group substituted with one or more halogen atoms, examples of which include, but are not limited to, trifluoromethyl, difluoromethyl, monofluoromethyl, chloroethyl (eg, , 2-chloroethyl), trifluoroethyl (including but not limited to, 2,2,2-trifluoroethyl), 2,2-difluoroethyl, 2-chloro-1-methylethyl, etc. .
  • cycloalkyl denotes a saturated monocyclic, bicyclic or tricyclic ring system containing from 3 to 12 ring carbon atoms.
  • the cycloalkyl group contains 3-10 ring carbon atoms, such as C 3-10 cycloalkyl; in other embodiments, the cycloalkyl group contains 3-8 ring carbon atoms, such as C 3- 8cycloalkyl , C3 - C8cycloalkyl , or (C3 - C8 )-cycloalkyl; in other embodiments, cycloalkyl contains 3-7 ring carbon atoms, such as C3-7 Cycloalkyl, C3 - C7cycloalkyl , or (C3 - C7 )-cycloalkyl; in yet other embodiments, cycloalkyl contains 3-6 ring carbon atoms, such as a C3-6 ring Alkyl, C3 - C6cycloalkyl or (C3 -
  • cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
  • C 3-8 cycloalkyl includes C 3-7 cycloalkyl
  • C 3-7 cycloalkyl includes C 3-6 cycloalkyl
  • the C 3-6 cycloalkane Radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • heterocyclyl and “heterocycle” are used interchangeably herein to refer to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic, bicyclic ring containing 3 to 12 ring atoms. or a tricyclic ring system wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms.
  • Ring sulfur atoms can optionally be oxidized to S-oxides.
  • the nitrogen atoms of the rings can be optionally oxidized to N-oxygen compounds.
  • Heterocyclyl groups include saturated heterocyclyl groups (ie, heterocycloalkyl groups) and partially unsaturated heterocyclyl groups.
  • heterocyclyl groups include, but are not limited to, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiazolidinyl, pyrazolidinyl, oxazolidinyl, imidazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl or morpholinyl, and the like.
  • the heterocyclyl group can be composed of 3-8 atoms or 3-6 atoms, the atoms are optionally selected from C, N, O or S and at least one atom is N, O or S; wherein, the heterocyclic group composed of 3-8 atoms includes a heterocyclic group composed of 3-6 atoms; the heterocyclic group composed of 3-6 atoms includes a heterocyclic group composed of 3-5 atoms Heterocyclyl.
  • the heterocyclic group consisting of 3-6 atoms includes, but is not limited to, oxiranyl, aziridinyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl , tetrahydrothienyl, thiazolidinyl, pyrazolidine, pyrazolinyl, oxazolidinyl, imidazolidinyl, piperidinyl, piperazinyl or morpholinyl and the like.
  • s typically describes the number of ring-forming atoms in a molecule in which the number of ring-forming atoms is s.
  • piperidinyl is a 6-atom heterocycloalkyl group
  • 1,2,3,4-tetrahydronaphthyl is a 10-atom carbocyclyl group.
  • heteroatom refers to O, S, N, P, and Si, including N, S, and P in any oxidation state; in the form of primary, secondary, tertiary amines, and quaternary ammonium salts; or on a nitrogen atom in a heterocyclic ring.
  • Hydrogen substituted form for example, N (like N in 3,4-dihydro-2H-pyrrolidinyl), NH (like NH in pyrrolidinyl) or NR (like in N-substituted pyrrolidinyl) NR, R is any suitable substituent).
  • aryl refers to monocyclic, bicyclic and tricyclic carbocyclic ring systems containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic A family of rings in which each ring system contains a ring of 3 to 7 atoms with one or more points of attachment to the rest of the molecule.
  • aryl is used interchangeably with the term “aromatic ring”. Examples of aryl groups may include phenyl, naphthyl, and anthracenyl. Unless otherwise specified, the group “ C6-10 aryl” refers to an aryl group containing 6-10 ring carbon atoms.
  • heteroaryl denotes monocyclic, bicyclic and tricyclic ring systems containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, wherein at least one ring is aromatic, and At least one ring contains 1, 2, 3 or 4 ring heteroatoms selected from nitrogen, oxygen, sulfur, and the heteroaryl group has one or more points of attachment to the rest of the molecule.
  • heteroaryl group can be attached to the remainder of the molecule (eg, the host structure in the formula) through any reasonable site (which can be C in CH, or N in NH).
  • heteroaryl may be used interchangeably with the terms “heteroaromatic ring” or “heteroaromatic”.
  • heteroaryl groups include, but are not limited to, furyl, imidazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, and the like.
  • the heteroaryl group is a heteroaryl group of 5-10 atoms, meaning that the heteroaryl group contains 1-9 ring carbon atoms and 1, 2, 3, or 4 atoms selected from O, S, and N Ring heteroatom; in other embodiments, heteroaryl is a heteroaryl group consisting of 5-6 atoms, meaning that the heteroaryl group contains 1-5 ring carbon atoms and 1, 2, 3, or 4 selected from O , S and N ring heteroatoms, examples of heteroaryl groups consisting of 5-6 atoms include, but are not limited to, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrazolyl, Pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl and the like.
  • prodrug refers to the conversion of a compound into a compound of formula (I), formula (II-A) or formula (II-B) in vivo. Such conversion is effected by hydrolysis of the prodrug in blood or enzymatic conversion to the parent structure in blood or tissue.
  • the prodrug compounds of the present invention can be esters.
  • esters that can be used as prodrugs include phenyl esters, aliphatic (C 1-24 ) esters, acyloxymethyl esters, carbonate esters , carbamates and amino acid esters.
  • a compound of the present invention contains a hydroxyl group, which can be acylated to give the compound in prodrug form.
  • prodrug forms include phosphates, such as these phosphates are phosphorylated by the hydroxyl group on the parent.
  • phosphates such as these phosphates are phosphorylated by the hydroxyl group on the parent.
  • a complete discussion of prodrugs can be found in the following literature: T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and SJ Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry , 2008, 51, 2328-2345.
  • Metal refers to a product obtained by metabolism of a specific compound or salt thereof in vivo. Metabolites of a compound can be identified by techniques well known in the art, and their activity can be characterized using assays as described herein. Such products may be obtained by subjecting the administered compound to oxidation, reduction, hydrolysis, amidation, deamidation, esterification, delipidation, enzymatic cleavage, and the like. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting a compound of the present invention with a mammal for a sufficient period of time.
  • pharmaceutically acceptable salts refer to organic and inorganic salts of the compounds of the present invention.
  • Pharmaceutically acceptable salts are well known in the art, as described in the literature: SM Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19.
  • Pharmaceutically acceptable non-toxic acid salts include, but are not limited to, inorganic acid salts formed by reaction with amino groups including hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, and organic acid salts such as acetate, oxalate, maleate, tartrate, citrate, succinate, malonate, or obtained by other methods such as ion exchange method described in books and literature these salts.
  • salts include adipate, alginate, ascorbate, aspartate, besylate, benzoate, bisulfate, borate, butyrate, camphoric acid Salt, camphorsulfonate, cyclopentylpropionate, digluconate, lauryl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphoric acid Salt, Gluconate, Hemisulfate, Heptanoate, Caproate, Hydroiodide, 2-Hydroxy-ethanesulfonate, Lacturonate, Lactate, Laurate, Lauryl Sulfate, Malate, Malonate, Mesylate, 2-Naphthalenesulfonate, Niacinate, Nitrate, Oleate, Palmitate, Pamoate, Pectate, Persulfate, 3 - Phenylpropionate, picrate, pivalate, propionate,
  • Salts obtained with appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
  • the present invention also contemplates the quaternary ammonium salts formed by any compound containing an N group. Water- or oil-soluble or dispersible products can be obtained by quaternization.
  • Alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Pharmaceutically acceptable salts further include appropriate, non-toxic ammonium, quaternary ammonium salts and amine cations that resist counterion formation, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C1 -C 8 sulfonates and aromatic sulfonates.
  • N-oxide in the present invention means that when the compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form an N-oxide.
  • N-oxides are N-oxides of tertiary amines or N-oxides containing nitrogen heterocyclic nitrogen atoms.
  • the corresponding amines can be treated with oxidizing agents such as hydrogen peroxide or peracids (eg, peroxycarboxylic acids) to form N-oxides (see Advanced Organic Chemistry, Wiley Interscience, 4th edition, Jerry March, pages).
  • oxidizing agents such as hydrogen peroxide or peracids (eg, peroxycarboxylic acids) to form N-oxides (see Advanced Organic Chemistry, Wiley Interscience, 4th edition, Jerry March, pages).
  • oxidizing agents such as hydrogen peroxide or peracids (eg, peroxycarboxylic acids) to form N-oxides (see Advanced Organic Chemistry, Wiley Interscience, 4th edition, Jerry March
  • a “solvate” of the present invention refers to an association of one or more solvent molecules with a compound of the present invention.
  • Solvate-forming solvents include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, ethanolamine, or mixtures thereof.
  • hydrate refers to an association in which the solvent molecule is water.
  • the term "hydrate" may be used.
  • one molecule of the compound of the present invention may be associated with one molecule of water, such as a monohydrate; in another embodiment, one molecule of the compound of the present invention may be associated with more than one molecule of water, such as a dihydrate In yet another embodiment, one molecule of a compound of the present invention may be associated with less than one molecule of water, such as a hemihydrate. It should be noted that the hydrates of the present invention retain the bioavailability of the non-hydrated form of the compounds.
  • treating any disease or disorder, in some of these embodiments, refers to ameliorating the disease or disorder (ie, slowing or arresting or alleviating the development of the disease or at least one clinical symptom thereof). In other embodiments, “treating” refers to alleviating or improving at least one physical parameter, including a physical parameter that may not be perceived by a patient. In other embodiments, “treating” refers to modulating a disease or disorder physically (eg, stabilizing an observable symptom) or physiologically (eg, stabilizing a physical parameter), or both. In other embodiments, “treating” refers to preventing or delaying the onset, occurrence or worsening of a disease or disorder.
  • prevent refers to a reduction in the risk of acquiring a disease or disorder (ie: stopping the development of at least one clinical symptom of a disease in a subject who may be facing or predisposed to facing the disease, but also not experience or exhibit symptoms of disease).
  • cardiovascular disease refers to the general term for cardiovascular and cerebrovascular diseases, describing the ischemic disease of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc. or bleeding disorders.
  • ischemic attack such as acute and chronic heart failure, arterial hypertension, coronary heart disease, stable and unstable angina, myocardial ischemia, myocardial infarction, shock, atherosclerosis, cardiac hypertrophy, cardiac fibrosis, atrial and ventricular arrhythmias , transient and ischemic attack, stroke, pre-eclampsia, inflammatory cardiovascular disease, peripheral and cardiovascular disease, peripheral perfusion disorders, pulmonary hypertension, coronary and peripheral arterial spasm, thrombosis, thromboembolic disease, edema development (eg, pulmonary edema, cerebral edema, renal edema, or heart failure-related edema) and restenosis (eg, in thrombolysis, percutaneous transluminal angioplasty (PTA), percutaneous coronary angioplasty (PTCA), heart transplantation and restenosis after bypass surgery), as well as microvascular and macrovascular injury (vasculitis), reperfusion injury, arterial and venous thrombosis, micro
  • the present invention relates to compounds having the structure of general formula (I), wherein the variables are as defined above.
  • the compound of the present invention may be a compound represented by formula (II-A) or formula (II-B), wherein the definitions of each variable are as described above.
  • stereoisomers Unless otherwise specified, the stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, Solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof are included within the scope of the present invention.
  • Compounds of the present disclosure may contain asymmetric or chiral centers and, therefore, may exist in different stereoisomeric forms.
  • the present invention is intended to make all stereoisomeric forms of compounds represented by formula (I), formula (II-A) or formula (II-B), including but not limited to diastereomers, enantiomers , atropisomers and geometric (or conformational) isomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention.
  • stereochemistry of any particular chiral atom when the stereochemistry of any particular chiral atom is not specified, then all stereoisomers of that structure are contemplated within the present invention and are included in the present invention as compounds disclosed herein .
  • stereochemistry is indicated by a solid wedge or a dashed line representing a particular configuration, then the stereoisomers of that structure are well defined and defined.
  • the compound represented by formula (I), formula (II-A) or formula (II-B) may exist in the form of a salt.
  • the salt refers to a pharmaceutically acceptable salt.
  • pharmaceutically acceptable means that a substance or composition must be chemically and/or toxicologically compatible with the other ingredients comprising the formulation and/or the mammal being treated with it.
  • the salts are not necessarily pharmaceutically acceptable salts, but can be used for the preparation and/or purification of compounds represented by formula (I), formula (II-A) or formula (II-B) and/or intermediates used to separate the enantiomers of the compounds represented by the formula (I), formula (II-A) or formula (II-B).
  • Pharmaceutically acceptable acid addition salts can be formed by reacting compounds of formula (I), formula (II-A) or formula (II-B) with inorganic or organic acids, such as acetate, aspartate, Benzoate, Benzenesulfonate, Bromide/Hydrobromide, Bicarbonate/Carbonate, Bisulfate/Sulfate, Camphorsulfonate, Chloride/HCl, Chlorophylline, Citrate, ethanedisulfonate, fumarate, glucoheptonate, gluconate, glucuronate, hippurate, hydroiodate/iodide, isethionate Salt, Lactate, Lacturonate, Lauryl Sulfate, Malate, Maleate, Malonate, Mandelate, Mesylate, Methyl Sulfate, Naphthoate, Naphthalene Sulfonate, Nicotinate, Nitrate, Octateate, Oleate, Oxalate, Palm
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid , ethanesulfonic acid, p-toluenesulfonic acid, sulfosalicylic acid, etc.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from Groups I to XII of the Periodic Table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include primary, secondary, and tertiary amines, and substituted amines include naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include, for example, isopropylamine, benzathine, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine, and tromethamine .
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, basic or acidic moieties, using conventional chemical methods.
  • such salts can be prepared by reacting the free acid forms of these compounds with a stoichiometric amount of a suitable base (eg, hydroxide, carbonate, bicarbonate, etc. of Na, Ca, Mg, or K), or by The preparations are carried out by reacting the free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a suitable base eg, hydroxide, carbonate, bicarbonate, etc. of Na, Ca, Mg, or K
  • Such reactions are usually carried out in water or an organic solvent or a mixture of the two.
  • non-aqueous media such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile is required.
  • non-aqueous media such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile.
  • the compounds disclosed herein, including their salts can also be obtained in their hydrate form or in a form containing a solvent (eg, ethanol, DMSO, etc.) for their crystallization.
  • a solvent eg, ethanol, DMSO, etc.
  • Compounds of the present disclosure may form solvates, inherently or by design, with pharmaceutically acceptable solvents, including water; thus, the present invention is intended to include both solvated and unsolvated forms.
  • Isotopically enriched compounds have the structures depicted by the general formulae given herein, except that one or more atoms are replaced by atoms having a selected atomic weight or mass number.
  • Exemplary isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O , 18 O, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I.
  • the compounds of the present invention include isotopically enriched compounds as defined in the present invention, for example, those compounds in which radioactive isotopes, such as 3 H, 14 C and 18 F are present, or in which non-radioactive isotopes, such as 2 H and 13 C.
  • isotopically enriched compounds can be used in metabolic studies (using 14 C), reaction kinetic studies (using eg 2 H or 3 H), detection or imaging techniques such as positron emission tomography (PET) or including drugs or Single photon emission computed tomography (SPECT) for substrate tissue distribution measurements, or may be used in radiation therapy of patients.
  • 18 F-enriched compounds are particularly ideal for PET or SPECT studies.
  • Isotopically enriched compounds of formula (I), formula (II-A) or formula (II-B) can be used by conventional techniques familiar to those skilled in the art or as described in the examples and preparation procedures of the present invention using suitable Isotopically labeled reagents are prepared in place of previously used unlabeled reagents.
  • substitution of heavier isotopes may provide certain therapeutic advantages that result from greater metabolic stability. For example, increased in vivo half-life or reduced dosage requirements or improved therapeutic index.
  • deuterium in the present invention is regarded as a substituent of the compound represented by formula (I), formula (II-A) or formula (II-B).
  • concentration of such heavier isotopes, especially deuterium can be defined by an isotopic enrichment factor.
  • isotopic enrichment factor refers to the ratio between the isotopic abundance and the natural abundance of a given isotope.
  • a substituent of a compound of the present invention is designated as deuterium
  • the compound has for each designated deuterium atom at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), At least 4500 (67.5% deuterium incorporated), at least 5000 (75% deuterium incorporated), at least 5500 (82.5% deuterium incorporated), at least 6000 (90% deuterium incorporated), at least 6333.3 (95% deuterium incorporated) deuterium incorporation), an isotopic enrichment factor of at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent may be isotopically substituted, eg, D2O , acetone - d6, DMSO -d6.
  • the present invention relates to intermediates for the preparation of compounds of formula (I), formula (II-A) or formula (II-B).
  • the present invention relates to methods for the preparation, isolation and purification of compounds represented by formula (I), formula (II-A) or formula (II-B).
  • the present invention provides a pharmaceutical composition, comprising a compound represented by formula (I), formula (II-A) or formula (II-B) or its stereoisomers, racemic or non-racemic isomers thereof mixture or a pharmaceutically acceptable salt or solvate thereof.
  • the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier, adjuvant or excipient, and optionally, other therapeutic and/or prophylactic ingredients.
  • Suitable carriers, adjuvants and excipients are well known to those skilled in the art and are described in detail in, for example, Ansel H.C. et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (2004) Lippincott, Williams & Wilkins, Philadelphia; Gennaro A.R. et al ., Remington: The Science and Practice of Pharmacy (2000) Lippincott, Williams & Wilkins, Philadelphia; and Rowe R.C., Handbook of Pharmaceutical Excipients (2005) Pharmaceutical Press, Chicago.
  • a method of treatment comprising the administration of a compound or pharmaceutical composition of the present invention, further comprising additional therapeutic agents, wherein said other active ingredients: calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin Antagonists, renin inhibitors, alpha-blockers, beta-blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors, diuretics, kinase inhibitors, matrix metalloproteinase inhibitors , soluble guanylate cyclase stimulators and activators, and phosphodiesterase inhibitors.
  • said other active ingredients calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin Antagonists, renin inhibitors, alpha-blockers, beta-blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors, diuretics, kinas
  • “Pharmaceutically acceptable excipient” as used in the present invention means a pharmaceutically acceptable material, admixture or vehicle that is relevant to the consistency of the administered dosage form or pharmaceutical composition.
  • Each excipient must, when mixed, be compatible with the other ingredients of the pharmaceutical composition to avoid interactions that would greatly reduce the efficacy of the disclosed compounds when administered to a patient and would result in a pharmaceutical composition that is not pharmaceutically acceptable Interaction.
  • each excipient must be pharmaceutically acceptable, eg, of sufficiently high purity.
  • Suitable pharmaceutically acceptable excipients will vary depending on the particular dosage form chosen. Furthermore, pharmaceutically acceptable excipients can be selected based on their particular function in the composition. For example, certain pharmaceutically acceptable excipients can be selected to aid in the production of a uniform dosage form. Certain pharmaceutically acceptable excipients may be selected to aid in the production of stable dosage forms. Certain pharmaceutically acceptable excipients may be selected which aid in carrying or transporting the compounds of the present invention from one organ or part of the body to another organ or part of the body when administered to a patient. Certain pharmaceutically acceptable excipients may be selected to enhance patient compliance.
  • Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents , solvent, co-solvent, suspending agent, emulsifier, sweetener, flavoring agent, taste masking agent, coloring agent, anti-caking agent, humectant, chelating agent, plasticizer, tackifier, antioxidant, Preservatives, stabilizers, surfactants and buffers.
  • excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents , solvent, co-solvent, suspending agent, emulsifier, sweetener, flavoring agent, taste masking agent, coloring agent, anti-caking agent, humectant, chelating agent, plasticizer, tackifier, antioxidant
  • pharmaceutically acceptable carriers can be solid or liquid carriers.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. Powders and tablets may contain from about 5% to about 95% of the active ingredient.
  • Suitable solid carriers are known in the art, for example, magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods for preparing various compositions can be found in: A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th ed ., 1990, Mack Publishing Company Co., Easton, Pennsylvania.
  • compositions disclosed herein are prepared using techniques and methods known to those skilled in the art. A description of some commonly used methods in the art can be found in Remington's Pharmaceutical Sciences (Mack Publishing Company).
  • the present invention relates to a process for preparing a pharmaceutical composition
  • a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, adjuvant, vehicle or combination thereof, the process comprising Mix various ingredients.
  • Pharmaceutical compositions containing compounds of the present disclosure can be prepared by mixing, for example, at ambient temperature and atmospheric pressure.
  • dosage forms include those suitable for the following routes of administration: (1) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, Solutions, emulsions, sachets, and cachets; (2) parenteral administration, such as sterile solutions, suspensions, and reconstituted powders; (3) transdermal administration, such as transdermal patches (4) rectal administration, such as suppositories; (5) inhalation, such as aerosols, solutions, and dry powders; and (6) topical administration, such as creams, ointments, lotions, solutions, pastes , sprays, foams and gels.
  • routes of administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, Solutions, emulsions, sachets, and cachets
  • parenteral administration such as sterile solutions, suspensions, and reconstituted powders
  • transdermal administration such as
  • compositions of the present invention may exist in free form for use in therapy or, if appropriate, in the form of their pharmaceutically acceptable derivatives.
  • pharmaceutically acceptable derivatives include pharmaceutically acceptable prodrugs, salts, esters, salts of these esters, or can provide, directly or indirectly, the invention described herein when administered to a patient in need thereof. Any additional adducts or derivatives of the compound or its metabolites or residues.
  • the compounds disclosed herein can be formulated into oral dosage forms. In another embodiment, the compounds disclosed herein may be formulated in an inhalation dosage form. In another embodiment, the compounds disclosed herein may be formulated for nasal administration. In yet another embodiment, the compounds disclosed herein may be formulated for transdermal administration. In yet another embodiment, the compounds disclosed herein may be formulated for topical administration.
  • compositions provided by the present invention can be provided as compressed tablets, triturated tablets, chewable lozenges, fast-dissolving tablets, recompressed tablets, enteric-coated tablets, sugar-coated or film-coated tablets.
  • Enteric-coated tablets are compressed tablets coated with a substance that resists the action of gastric acid but dissolves or disintegrates in the intestine, thus preventing the active ingredient from contacting the acidic environment of the stomach.
  • Enteric coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalate.
  • Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which can help mask unpleasant taste or odor and prevent tablet oxidation.
  • Film-coated tablets are compressed tablets covered with a thin layer or film of a water-soluble substance.
  • Film coatings include, but are not limited to, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coatings impart the same general properties as sugar coatings.
  • Multiplexed tablets are compressed tablets prepared by more than one compression cycle, including multi-layer, compression-coated, or dry-coated tablets.
  • Tablet dosage forms may be prepared from the active ingredient in powdered, crystalline or granular form, alone or in combination with one or more of the carriers or excipients described herein, including binders, disintegrating disintegrants, controlled release polymers, lubricants, diluents and/or colorants. Flavoring and sweetening agents are especially useful in forming chewable tablets and lozenges.
  • the pharmaceutical compositions provided by the present invention can be provided in soft capsules or hard capsules, which can be prepared from gelatin, methylcellulose, starch or calcium alginate.
  • the hard gelatin capsules also known as dry-filled capsules (DFC), consist of two segments, one inserted into the other, thus completely encapsulating the active ingredient.
  • Soft elastic capsules SEC are soft, spherical shells, such as gelatin shells, which are plasticized by the addition of glycerol, sorbitol or similar polyols.
  • Soft gelatin shells may contain preservatives to prevent microbial growth. Suitable preservatives are those described herein, including methyl and propyl parabens, and sorbic acid.
  • liquid, semi-solid and solid dosage forms provided by the present invention can be encapsulated in capsules.
  • suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils or triglycerides.
  • Capsules containing such solutions can be prepared as described in US Patents U.S. Pat. Nos. 4,328,245; 4,409,239 and 4,410,545.
  • the capsules may also be coated as known to those skilled in the art to improve or maintain active ingredient dissolution.
  • compositions provided herein can be provided in liquid and semi-solid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups.
  • Emulsions are two-phase systems in which one liquid is completely dispersed in the other liquid in the form of pellets, which can be either oil-in-water or water-in-oil.
  • Emulsions may include pharmaceutically acceptable non-aqueous liquids and solvents, emulsifiers and preservatives.
  • Suspensions may include pharmaceutically acceptable suspending agents and preservatives.
  • the aqueous alcoholic solution may include pharmaceutically acceptable acetals, such as di(lower alkyl) acetals of lower alkyl aldehydes, such as acetaldehyde diethyl acetal; and water-soluble solvents having one or more hydroxyl groups, such as Propylene Glycol and Ethanol. Elixirs are clear, sweetened hydroalcoholic solutions.
  • a syrup is an aqueous solution of a concentrated sugar such as sucrose, and may also contain a preservative.
  • solutions in polyethylene glycol can be diluted with a sufficient amount of a pharmaceutically acceptable liquid carrier, such as water, for precise and convenient administration.
  • compositions provided by the present invention can be formulated into any dosage form suitable for inhalation administration to patients, such as dry powder, aerosol, suspension or solution compositions.
  • the pharmaceutical compositions disclosed herein may be formulated in a dosage form suitable for inhalation administration to a patient as a dry powder.
  • the pharmaceutical compositions disclosed herein may be formulated in a dosage form suitable for inhalation administration to a patient via a nebulizer.
  • Dry powder compositions for delivery to the lungs by inhalation typically comprise a finely powdered compound of the present disclosure and one or more finely powdered pharmaceutically acceptable excipients.
  • excipients that are particularly suitable for use as dry powders are known to those skilled in the art and include lactose, starch, mannitol, and mono-, di- and polysaccharides. Fine powders can be prepared, for example, by micronization and grinding. In general, size-reduced (eg, micronized) compounds can be defined by D50 values (eg, as measured by laser diffraction) of about 1 to 10 microns.
  • compositions suitable for transdermal administration may be prepared as discrete patches intended to remain in intimate contact with the epidermis of a patient for an extended period of time.
  • the active ingredient can be delivered from the patch by iontophoresis, as generally described in Pharmaceutical Research, 3(6), 318 (1986).
  • compositions suitable for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • ointments, creams and gels can be formulated with an aqueous or oily base, and a suitable thickening and/or gelling agent and/or solvent.
  • bases may include, water, and/or oils such as liquid paraffin and vegetable oils (eg, peanut oil or castor oil), or solvents such as polyethylene glycols.
  • Thickening and gelling agents used depending on the nature of the base include soft paraffin, aluminium stearate, cetearyl alcohol, polyethylene glycol, lanolin, beeswax, carbopol and cellulose derivatives, and/or mono Glyceryl stearate and/or nonionic emulsifiers.
  • the compounds of the present invention can also be combined with soluble polymers as targetable drug carriers.
  • soluble polymers include polyvinylpyrrolidone, pyran copolymers, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyoxyethylene polylysine substituted with palmitoyl residues.
  • the compounds disclosed herein can be combined with a class of biodegradable polymers used in achieving controlled release of drugs, eg, polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters , crosslinked or amphiphilic block copolymers of polyacetal, polydihydropyran, polycyanoacrylate and hydrogel.
  • compositions provided herein can be formulated in any dosage form suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems and in liquid prior to injection Solid forms are prepared as solutions or suspensions.
  • dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical sciences (see Remington: The Science and Practice of Pharmacy, supra).
  • compositions intended for parenteral administration may include one or more pharmaceutically acceptable carriers and excipients including, but not limited to, aqueous carriers, water-miscible carriers, non-aqueous carriers, anti- Microbial or anti-microbial growth preservatives, stabilizers, dissolution enhancers, isotonicity agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, polyvalent Chelating or sequestering agents, antifreeze agents, cryoprotectants, thickeners, pH adjusters and inert gases.
  • aqueous carriers water-miscible carriers
  • non-aqueous carriers non-aqueous carriers
  • anti- Microbial or anti-microbial growth preservatives stabilizers, dissolution enhancers, isotonicity agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, polyvalent Chelating or
  • the pharmaceutical composition provided by the present invention can be administered by rectal suppository, by mixing the medicine with a suitable non-irritating excipient (such as cocoa butter, glycerides synthesized from polyethylene glycol), it is solid at room temperature, and then It liquefies or dissolves in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, glycerides synthesized from polyethylene glycol
  • compositions provided by the present invention can be formulated into immediate or modified release dosage forms, including delayed-, sustained-, pulsed-, controlled-, targeted- and programmed-release forms.
  • the term "therapeutically effective amount” refers to the total amount of each active ingredient sufficient to exhibit a beneficial therapeutic effect. For example, an amount sufficient to treat, cure or reduce symptoms of a disease is administered or brought into balance in the body.
  • the effective amount required for a particular treatment regimen will depend on a number of factors, including the disease being treated, the severity of the disease, the activity of the particular drug used, the mode of administration, the clearance of the particular drug, the duration of treatment, the combination of medications, age , weight, gender, diet and patient health, etc.
  • a compound of the invention can readily determine the appropriate dose of a compound of the invention to administer to a patient, and may vary depending on the patient's health, age, weight, frequency of administration, other active ingredients use and/or indications for the compound to be administered.
  • Dosages of the compounds of the present invention may range from about 0.001 to 500 mg/kg body weight/day.
  • the amount of active compound in a unit dose of the formulation can be varied or adjusted according to the particular application.
  • a typical recommended daily dosing regimen may range from about 1 mg/day to about 500 mg/day in two to four divided doses.
  • administration refers to the provision of a therapeutically effective amount of a drug to an individual by means of oral, sublingual, intravenous, subcutaneous, transdermal, intramuscular, intradermal, intrathecal, epidural, intraocular, intracranial, Inhalation, rectal, vaginal, etc.
  • Dosage forms include ointments, lotions, tablets, capsules, pills, dispersible powders, granules, suppositories, pills, lozenges, injections, sterile solutions or non-aqueous solutions, suspensions, emulsions, patches agent, etc.
  • the active ingredient is combined with a non-toxic pharmaceutically acceptable carrier (such as glucose, lactose, acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, silica gel, potato starch, urea , dextran, etc.) complex.
  • a non-toxic pharmaceutically acceptable carrier such as glucose, lactose, acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, silica gel, potato starch, urea , dextran, etc.
  • the preferred route of administration will vary with clinical characteristics, dosage changes must depend on the condition of the patient being treated, and the appropriate dosage will be determined by the physician on a case-by-case basis.
  • the therapeutically effective amount per unit dose depends on body weight, physiology and the chosen vaccination regimen.
  • Compound per unit dose refers to the weight of the compound per administration, excluding the weight of the carrier (which is contained in the drug).
  • compositions provided by the present invention can be formulated for single-dose or multiple-dose administration.
  • the single-dose formulation is packaged in ampoules, vials or syringes.
  • the multiple-dose parenteral formulation must contain a bacteriostatic or fungistatic concentration of the antimicrobial agent. All parenteral formulations must be sterile, as known and practiced in the art.
  • compositions provided by the present invention can be co-formulated with other active ingredients that do not impair the intended therapeutic effect, or with substances that supplement the intended effect.
  • the methods of treatment of the present invention comprise administering to a patient in need thereof a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention.
  • Various embodiments of the present invention encompass the treatment of diseases referred to herein by administering to a patient in need thereof a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention.
  • a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention may be administered by any suitable route of administration, including systemic and topical administration.
  • Systemic administration includes oral, parenteral, transdermal, and rectal administration.
  • Typical parenteral administration refers to administration by injection or infusion, including intravenous, intramuscular and subcutaneous injection or infusion.
  • Topical administration includes application to the skin as well as intraocular, otic, intravaginal, inhalation and intranasal administration.
  • a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention may be administered orally.
  • a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention may be administered by inhalation.
  • a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention may be administered intranasally.
  • a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention may be administered once, or several times at different time intervals over a specified period of time, depending on the dosing regimen. For example, it is administered once, twice, three times or four times a day. In one embodiment, the administration is once a day. In yet another embodiment, the administration is twice daily. Administration may be performed until the desired therapeutic effect is achieved or maintained indefinitely.
  • a suitable dosing regimen for a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention depends on the pharmacokinetic properties of the compound, such as absorption, distribution and half-life, which can be determined by the skilled artisan.
  • a suitable dosing regimen for a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention depends on the disease being treated, the severity of the disease being treated, the age and physical condition of the patient being treated , the medical history of the patient being treated, the nature of concomitant therapy, the desired therapeutic effect, etc., factors within the knowledge and experience of the technician.
  • adjustments to appropriate dosing regimens may be required as individual patient responses to dosing regimens or as individual patient needs change over time.
  • the compounds of the present invention may be administered concurrently with, before or after one or more other therapeutic agents.
  • the compounds of the present invention can be administered separately with other therapeutic agents by the same or different route of administration, or in the same pharmaceutical composition. This is selected by those skilled in the art according to the actual conditions of the patient's health, age, weight and other physical conditions. If formulated as a fixed dose, such combination products employ the compounds of the invention (within the dosage ranges described herein) and the other pharmaceutically active agents (within their dosage ranges).
  • the present invention includes combinations comprising an amount of at least one compound of the present invention, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, and an effective amount of one or more of the foregoing Additional therapeutic agents.
  • the compounds of the present invention may be administered in prodrug form.
  • the "prodrug" of the compound of the present invention is a functional derivative that can finally release the compound of the present invention in vivo when administered to a patient.
  • those skilled in the art can implement one or more of the following methods: (a) altering the in vivo onset time of the compound; (b) altering the in vivo duration of action of the compound; (c) altering in vivo delivery or distribution of the compound; (d) altering the in vivo solubility of the compound; and (e) overcoming side effects or other difficulties faced by the compound.
  • Typical functional derivatives used to prepare prodrugs include variants of compounds that are chemically or enzymatically cleaved in vivo. These variants, including the preparation of phosphates, amides, esters, thioesters, carbonates and carbamates, are well known to those skilled in the art.
  • the compounds and pharmaceutical compositions provided by the present invention can be used to prepare medicines for inhibiting chymotrypsin, and can also be used to prepare medicines for the treatment or prevention of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, renal failure, renal disease, internal organs fibrotic disorders and skin fibrotic diseases.
  • diseases of the cardiovascular system or cardiovascular diseases are understood to mean diseases such as the following: acute and chronic heart failure, arterial hypertension, coronary heart disease, stable and unstable angina, myocardial ischemia , myocardial infarction, shock, atherosclerosis, cardiac hypertrophy, cardiac fibrosis, atrial and ventricular arrhythmias, transient and ischemic attacks, stroke, pre-eclampsia, inflammatory cardiovascular disease, peripheral and cardiovascular disease, Peripheral perfusion disturbance, pulmonary hypertension, coronary and peripheral arterial spasm, thrombosis, thromboembolic disease, development of edema (eg, pulmonary edema, cerebral edema, renal edema, or edema associated with heart failure), and restenosis (eg, during thrombolytic therapy , percutaneous transluminal angioplasty (PTA), percutaneous coronary angioplasty (PTCA), restenosis after heart transplantation and bypass surgery), as well as microvascular and
  • heart failure also includes more specific or related types of disease, such as acute decompensated heart failure, right heart failure, left heart failure, global failure, ischemic cardiomyopathy, dilated heart failure Cardiomyopathy, congenital heart defects, heart valve defects, heart failure associated with heart valve defects, mitral valve stenosis, mitral regurgitation, aortic stenosis, aortic regurgitation, tricuspid stenosis, tricuspid Valve insufficiency, pulmonary stenosis, pulmonary insufficiency, combined heart valve defects, myocardial inflammation (myocarditis), chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, cardiac storage disorders, and diastolic and Systolic heart failure.
  • myocardial inflammation myocarditis
  • chronic myocarditis chronic myocarditis
  • acute myocarditis acute myocarditis
  • viral myocarditis
  • the compounds of the present invention may be applied, but in no way limited to, the use of an effective amount of the compounds or pharmaceutical compositions of the present invention to be administered to a patient to prevent, treat or alleviate chymotrypsin-related diseases.
  • the chymotrypsin-related diseases further include, but are not limited to, heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, renal failure, renal disease, fibrotic disorders of internal organs, and skin fibrosis.
  • the compounds and pharmaceutical compositions of the present invention may also be used in veterinary treatment of mammals in pets, introduced species and farm animals. Examples of other animals include horses, dogs and cats.
  • the compounds of the present invention include pharmaceutically acceptable derivatives thereof.
  • the compounds of the present invention can be prepared by the methods described in the present invention, unless otherwise specified, wherein the substituents are as defined in formula (I), formula (II-A) or formula (II-B) .
  • the following reaction schemes and examples serve to further illustrate the content of the present invention.
  • the measurement conditions for low-resolution mass spectrometry (MS) data are: Agilent 6120 quadrupole HPLC-M (column model: Zorbax SB-C18, 2.1 ⁇ 30 mm, 3.5 microns, 6 min, flow rate 0.6 mL/min.
  • Mobile phase 5 %-95% ( CH3CN with 0.1% formic acid) in ( H2O with 0.1% formic acid) using electrospray ionization (ESI) at 210 nm/254 nm with UV detection.
  • ESI electrospray ionization
  • the synthesis of the compound represented by the formula (IA-1) can refer to patent application CN105658647A, and then the compound represented by the formula (IA-1) and the compound represented by the formula (IA-2) are subjected to an amide condensation reaction to obtain the compound represented by the formula (IA). target product shown.
  • the carboxylic acid compound (the compound represented by the formula (IA-1)) is reacted with different amines (such as different sulfonamides) to obtain the following example compounds, wherein the obtained product structure and its characterization data
  • different amines such as different sulfonamides
  • Example A Enzymatic assay of chymotrypsin-like
  • the enzyme source used was recombinant human chymotrypsin (sigma), and the chymotrypsin-like substrate used was N-succinyl-Ala-Ala-Pro-Phe-7-amido-4-methylcoumarin.
  • test substance Dilute the test substance with DMSO, mix 20nL test substance (1000X) and 10 ⁇ L enzyme solution (2X) in a 384-well plate, incubate at room temperature for 15 minutes, then add substrate solution (2X), use Synergy 2 for dynamic Read the fluorescence signal excited at 370 nm followed by emission at 460 nm.
  • Example number IC50 (nM) Example number IC50 (nM) 1 2.3 2 2.2 4 2.6 5 32.3 6 39.2 7 13.0 10 40.0

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une classe de dérivés d'uracile multi-substitués et une composition pharmaceutique contenant de tels composés, lesdits composés pouvant être utilisés en tant qu'inhibiteurs de chymases. L'invention concerne également un procédé de préparation de tels composés et de la composition pharmaceutique et leur utilisation dans la préparation d'un médicament pour le traitement de maladies cardiovasculaires associées, telles que l'insuffisance cardiaque ou l'infarctus du myocarde.
PCT/CN2021/140771 2020-12-25 2021-12-23 Dérivés d'uracile multi-substitués et leur utilisation WO2022135514A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011559260.4 2020-12-25
CN202011559260 2020-12-25

Publications (1)

Publication Number Publication Date
WO2022135514A1 true WO2022135514A1 (fr) 2022-06-30

Family

ID=82136233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/140771 WO2022135514A1 (fr) 2020-12-25 2021-12-23 Dérivés d'uracile multi-substitués et leur utilisation

Country Status (2)

Country Link
CN (1) CN114685472B (fr)
WO (1) WO2022135514A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104395310A (zh) * 2012-05-09 2015-03-04 拜耳药业股份公司 二环取代尿嘧啶及其用途
CN105873919A (zh) * 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶
CN105899500A (zh) * 2013-11-08 2016-08-24 拜耳医药股份有限公司 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途
CN105980381A (zh) * 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104395310A (zh) * 2012-05-09 2015-03-04 拜耳药业股份公司 二环取代尿嘧啶及其用途
CN105873919A (zh) * 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶
CN105899500A (zh) * 2013-11-08 2016-08-24 拜耳医药股份有限公司 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途
CN105980381A (zh) * 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途

Also Published As

Publication number Publication date
CN114685472B (zh) 2024-04-26
CN114685472A (zh) 2022-07-01

Similar Documents

Publication Publication Date Title
EP1353662B1 (fr) Procedes relatifs au traitement de maladies par le biais d'inhibiteurs de malonyl-coa decarboxylase
ES2526981T3 (es) N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
KR102515248B1 (ko) 오토탁신 억제제 화합물
ES2532356T3 (es) N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
KR102558308B1 (ko) 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
JP5440934B2 (ja) 置換プテリジン
KR101723707B1 (ko) Ｐｇｄｓ 저해 작용을 갖는 피페라진 화합물
BR112014030284B1 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
EA031061B1 (ru) Соединения и композиции в качестве ингибиторов киназ
WO2011135303A2 (fr) Modulateurs d'ubiquitination
KR102418211B1 (ko) 일시적 수용체 전위 a1 이온 채널의 억제
JP2008521775A (ja) 炎症性疾患治療用の置換プテリジン
ES2968822T3 (es) Azetidina dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
BR112020025701A2 (pt) Processo de produção e intermediários para um composto de pirrolo[2,3-d]pirimidina e seu uso
US20160304486A1 (en) Indoline compounds as aldosterone synthase inhibitors
US11981681B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
ES2886641T3 (es) Inhibidores de citocromo P450 y sus usos
WO2020125779A1 (fr) Dérivés de styryl xanthine substitués en position 8 et leurs utilisations
KR20140105598A (ko) [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도
CN114685472B (zh) 多取代的尿嘧啶衍生物及其用途
EA030709B1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
WO2022135502A1 (fr) Dérivé d'uracile à substitution multiple et son utilisation
ES2968824T3 (es) Tetrahidropirano dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
CN114671878B (zh) 取代的含氮双环化合物及其用途
CN112010818A (zh) 吗啉酰胺衍生物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21909509

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21909509

Country of ref document: EP

Kind code of ref document: A1